The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Alexander Tenenbaum

Cardiac Rehabilitation Institute

Sheba Medical Center





Name/email consistency: high



  • Cardiac Rehabilitation Institute, Sheba Medical Center, Tel-Hashomer, 52621, Israel. 2003 - 2012
  • Sackler Faculty of Medicine, Tel-Aviv University, Israel. 2010


  1. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Tenenbaum, A., Fisman, E.Z. Cardiovasc. Diabetol (2012) [Pubmed]
  2. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? Tenenbaum, A., Fisman, E.Z. Cardiovasc. Diabetol (2012) [Pubmed]
  3. Systematic review: Very-low-strength evidence suggests that combining ezetimibe or fibrate with statins is no more effective than high-dose statin monotherapy for reducing all-cause mortality. Tenenbaum, A., Fisman, E.Z. Evid. Based. Med (2010) [Pubmed]
  4. Optimal management of combined dyslipidemia: what have we behind statins monotherapy? Tenenbaum, A., Fisman, E.Z., Motro, M., Adler, Y. Adv. Cardiol (2008) [Pubmed]
  5. Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease? Tenenbaum, A., Boyko, V., Fisman, E.Z., Goldenberg, I., Adler, Y., Feinberg, M.S., Motro, M., Tanne, D., Shemesh, J., Schwammenthal, E., Behar, S. Cardiovasc. Diabetol (2008) [Pubmed]
  6. Insulin resistance is associated with increased risk of major cardiovascular events in patients with preexisting coronary artery disease. Tenenbaum, A., Adler, Y., Boyko, V., Tenenbaum, H., Fisman, E.Z., Tanne, D., Lapidot, M., Schwammenthal, E., Feinberg, M.S., Matas, Z., Motro, M., Behar, S. Am. Heart J. (2007) [Pubmed]
  7. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Tenenbaum, A., Fisman, E.Z., Motro, M., Adler, Y. Cardiovasc. Diabetol (2006) [Pubmed]
  8. Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Tenenbaum, A., Motro, M., Fisman, E.Z., Adler, Y., Shemesh, J., Tanne, D., Leor, J., Boyko, V., Schwammenthal, E., Behar, S. Eur. Heart J. (2005) [Pubmed]
  9. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Tenenbaum, A., Motro, M., Fisman, E.Z. Cardiovasc. Diabetol (2005) [Pubmed]
  10. Smoking and development of type 2 diabetes in patients with decreased functional capacity. Tenenbaum, A., Fisman, E.Z., Adler, Y., Motro, M., Boyko, V., Behar, S. Int. J. Cardiol. (2005) [Pubmed]
  11. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Tenenbaum, A., Motro, M., Fisman, E.Z., Schwammenthal, E., Adler, Y., Goldenberg, I., Leor, J., Boyko, V., Mandelzweig, L., Behar, S. Circulation (2004) [Pubmed]
  12. Macrovascular complications of metabolic syndrome: an early intervention is imperative. Tenenbaum, A., Motro, M., Schwammenthal, E., Fisman, E.Z. Int. J. Cardiol. (2004) [Pubmed]
  13. Functional capacity impairment in patients with coronary artery disease: prevalence, risk factors and prognosis. Tenenbaum, A., Motro, M., Fisman, E.Z., Leor, J., Boyko, V., Mandelzweig, L., Behar, S. Cardiology (2003) [Pubmed]
WikiGenes - Universities